Home > Insider Trading > Filing (0001209191-16-095845)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1197032	F Ian Smith	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-02-02	17,299	$0.01	125,083	No	4	A	Direct
Common Stock	Disposition	2016-02-03	5,000	$89.90	120,083	No	4	S	Direct
Common Stock	Disposition	2016-02-03	4,232	$90.97	115,851	No	4	S	Direct
Common Stock	Disposition	2016-02-03	1,200	$91.68	114,651	No	4	S	Direct
Common Stock	Disposition	2016-02-03	1,652	$92.73	112,999	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2016-02-02	34,482	$0.00	34,482	$91.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
34,482		2016-02-01	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,306	Indirect	401(k)

Footnotes

Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $89.90 (range $89.31 to $90.27).
Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $90.97 (range $90.32 to $91.30).
Open market sales reported on this line occurred at a weighted average price of $91.68 (range $91.33 to $92.23).
Open market sales reported on this line occurred at a weighted average price of $92.73 (range $92.34 to $93.20).
The option vests in 16 quarterly installments from 02/02/2016.